ArticleScientific reports2026
Probing the structure and molecular docking of a Cu(II)-glutamic acid complex as a metallodrug agent using spectroscopic, electrochemical and theoretical studies.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
A copper(II) complex with L-glutamic acid was synthesized and comprehensively characterized to elucidate its structural, electronic, redox, thermal, and biological interaction properties. FT-IR analysis confirmed coordination through carboxylate oxygen and amino nitrogen atoms, evidenced by shifts in ν_as(COO⁻) and ν_s(COO⁻) bands along with the appearance of Cu-O and Cu-N vibrational modes. The electronic spectrum of the Cu(II) complex exhibits a broad and low-intensity d-d transition in the 600-800 nm region, which is characteristic of a Jahn-Teller distorted octahedral geometry; this assignment is further supported by the observed effective magnetic moment (µ_eff = 2.46 BM), consistent with a d⁹ Cu(II) system. Fluorescence analysis shows an emission maximum in the 430-460 nm range with a Stokes shift of approximately 70-100 nm, indicating significant excited-state relaxation and ligand field perturbation arising from coordination of glutamic acid to the Cu(II) center. Thermogravimetric analysis showed major decomposition steps between 167 and 187 °C, confirming the thermal stability of the coordinated framework. Molar conductivity measurements indicated weak electrolyte behavior, suggesting the predominance of a neutral complex species in solution. Cyclic voltammetry demonstrated a quasi-reversible Cu(II)/Cu(I) redox couple with ligand-dependent potential shifts, reflecting coordination-induced modulation of electron density at the metal center. Molecular docking investigations revealed enhanced receptor binding affinity of the Cu(II) complex compared to free glutamic acid, with calculated binding energies reaching up to - 9.20 kcal·mol⁻¹, accompanied by strengthened hydrogen bonding and electrostatic interactions within receptor binding pockets. These combined results establish a clear structure-electronic-biological correlation, demonstrating that coordination-induced changes in electronic structure and redox properties directly influence the binding affinity and interaction behavior of the complex with biological targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.